For investors in healthcare stocks, 1995 was a much-needed shotin the arm that remedied a three-year period of falling shareprices. An annual survey by WDI Capital Markets of Hilton Head,SC, saw a strong surge in share prices among healthcare
For investors in healthcare stocks, 1995 was a much-needed shotin the arm that remedied a three-year period of falling shareprices. An annual survey by WDI Capital Markets of Hilton Head,SC, saw a strong surge in share prices among healthcare companieslast year. Vendors of cardiac instruments led the charge in stockvaluation growth, although manufacturers of medical imaging devicesturned in a strong performance as well.
For the year, overall healthcare industry share prices leaped40.1%, compared with a 4.7% decline in 1994. Share prices dropped9.4% in 1993 and 10.6% in 1992.
Among public imaging device companies, stock prices trackedby WDI climbed 75.8% in 1995, compared with a lackluster gainof 1.2% in 1994. ThermoTrex led the segment with share-price growthof 270%, while bone densitometry firm Hologic jumped 173%. Othervendors turning in strong performances for the year were bonedensitometry vendor Lunar, up 129%; image-guided catheter manufacturerEndosonics, up 122%; x-ray vendor Fischer Imaging, up 85%; andnuclear medicine firm ADAC Laboratories, up 55%.
Imaging services firms also enjoyed rising stock valuations,according to WDI's survey. Share prices in the segment rose anaverage of 52.2% for the year.
In other WDI news, the investment and advisory firm announcedthat former Fischer Imaging executive Robert Cascella has joinedthe company as president.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.